Allogene CAR-T Data Advances Off-the-Shelf Lymphoma Treatment
Allogene Therapeutics CMO Zach Roberts presented new study results for the company's off-the-shelf CAR-T therapy targeting B-cell lymphoma, an allogeneic approach that bypasses patient-specific cell manufacturing. If validated further, the model could lower treatment costs and shorten time to therapy versus